Other analysts have also recently issued research reports about the company. Robert W. Baird reiterated an outperform rating and set a $157.00 price objective on shares of Amgen in a research report on Friday, August 26th. Jefferies Group reiterated a buy rating and set a $198.00 price objective on shares of Amgen in a research report on Tuesday, August 23rd. Gabelli initiated coverage on Amgen in a research report on Friday, August 26th. They set a hold rating for the company. Leerink Swann reiterated a hold rating on shares of Amgen in a research report on Sunday, June 26th. Finally, Vetr cut Amgen from a strong-buy rating to a buy rating and set a $175.53 price objective for the company. in a research report on Monday, May 30th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and twelve have given a buy rating to the stock. The company presently has an average rating of Buy and a consensus price target of $184.56.
Shares of Amgen (NASDAQ:AMGN) opened at 175.62 on Monday. Amgen has a 12-month low of $130.09 and a 12-month high of $176.64. The firm has a 50 day moving average price of $172.03 and a 200 day moving average price of $159.88. The stock has a market cap of $131.43 billion, a PE ratio of 17.97 and a beta of 0.87.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Wednesday, July 27th. The medical research company reported $2.84 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.74 by $0.10. Amgen had a return on equity of 29.30% and a net margin of 33.07%. The firm earned $5.69 billion during the quarter, compared to analysts’ expectations of $5.58 billion. During the same quarter in the previous year, the business earned $2.57 earnings per share. The company’s revenue was up 5.9% on a year-over-year basis. On average, equities analysts expect that Amgen will post $11.36 EPS for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 8th. Shareholders of record on Wednesday, August 17th were paid a dividend of $1.00 per share. The ex-dividend date of this dividend was Monday, August 15th. This represents a $4.00 dividend on an annualized basis and a dividend yield of 2.28%. Amgen’s payout ratio is currently 40.90%.
In other Amgen news, VP Annette Louise Such sold 3,000 shares of Amgen stock in a transaction dated Tuesday, August 2nd. The stock was sold at an average price of $174.59, for a total transaction of $523,770.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.20% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in AMGN. Macquarie Group Ltd. raised its position in Amgen by 3.6% in the second quarter. Macquarie Group Ltd. now owns 105,159 shares of the medical research company’s stock worth $16,000,000 after buying an additional 3,625 shares during the last quarter. Carnick & Kubik Group LLC acquired a new position in shares of Amgen during the second quarter valued at $2,307,000. Williams Jones & Associates LLC raised its position in shares of Amgen by 399.6% in the second quarter. Williams Jones & Associates LLC now owns 71,431 shares of the medical research company’s stock valued at $10,868,000 after buying an additional 57,132 shares in the last quarter. Kentucky Retirement Systems Insurance Trust Fund acquired a new position in shares of Amgen during the second quarter valued at $4,615,000. Finally, Kentucky Retirement Systems acquired a new position in shares of Amgen during the second quarter valued at $9,720,000. Institutional investors and hedge funds own 79.15% of the company’s stock.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.